WO2020035079A1 - 具有心脑血管保护功能的多肽及其制备方法与应用 - Google Patents

具有心脑血管保护功能的多肽及其制备方法与应用 Download PDF

Info

Publication number
WO2020035079A1
WO2020035079A1 PCT/CN2019/106234 CN2019106234W WO2020035079A1 WO 2020035079 A1 WO2020035079 A1 WO 2020035079A1 CN 2019106234 W CN2019106234 W CN 2019106234W WO 2020035079 A1 WO2020035079 A1 WO 2020035079A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
amino acid
modification
cardio
protection function
Prior art date
Application number
PCT/CN2019/106234
Other languages
English (en)
French (fr)
Inventor
韩利文
张姗姗
刘可春
李晓彬
张轩铭
侯海荣
孙晨
Original Assignee
山东省科学院生物研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 山东省科学院生物研究所 filed Critical 山东省科学院生物研究所
Publication of WO2020035079A1 publication Critical patent/WO2020035079A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention relates to a polypeptide with cardio-cerebral vascular protection function, a preparation method and application thereof, and belongs to the technical field of functional polypeptides.
  • NCDs chronic non-communicable diseases
  • diabetes cancer
  • cardiovascular and cerebrovascular diseases As the population ages and the socio-economic and lifestyle changes continue, the incidence of noncommunicable diseases will continue to increase. The number of deaths related to noncommunicable diseases is expected to increase to 52 million by 2030.
  • ROS reactive oxygen species
  • ROS reactive oxygen species
  • many synthetic antioxidants limit their use due to their potential health-related risks. Therefore, natural dietary antioxidants are the best choice due to their beneficial effects and higher safety.
  • Marine animals and plants There are many species of marine animals and plants, rich in biologically active substances. Marine animals and plants are considered to be a treasure trove of new types of bioactive compounds due to their significantly different living environments compared to those of terrestrial origin. A large number of studies have shown that marine bioactive peptides with anti-oxidant, anti-hypertensive, anti-diabetic, anti-bacterial and anti-tumor biological activities have high potential value and can be used to prevent and treat non-infectious diseases. In addition, as consumers' awareness of nutrition and health continues to increase, the demand for functional foods and nutritional supplements is also growing. Recent research has increasingly focused on bioactive peptides isolated from diet-derived marine organisms.
  • Molluscs are the second largest animal species on the planet. It not only plays an important role in maintaining ecological balance, but also has great commercial value as an edible animal resource. There are many potential active compounds in mollusks that can be used in dietary supplements, functional foods, nutritional products and medicines. However, there are few published studies on the isolation of potential active compounds from mollusks with application value.
  • Neptunea arthritica cumingii belongs to Mollusca, Gastropoda, Neogastropoda, and Buccinida. It is a large predatory gastropod. It mainly lives in China, Japan, North Korea and South Korea at 10 to 78 meters deep. In China, snails are mainly distributed in the Yellow Sea and Bohai Sea regions, especially Dalian, Liaoning and Penglai, Shandong. The fleshy snails have firm and dense meat, delicious taste, high nutritional value, but low hatchability, so they have high commercial value.
  • snail saliva contains tetramine, and histamine and choline derivatives are neuroactive.
  • the present invention provides a polypeptide with cardio-cerebral vascular protection function, and a preparation method and application thereof.
  • a polypeptide with cardio-cerebral vascular protection function The amino acid sequence is shown in SEQ ID NO.1.
  • SEQ ID NO. 1 Tyr-Ile-Ala-Glu-Asp-Ala-Glu-Arg.
  • the amidation modification is an acetylation modification at the N-terminal amino acid residue at the first position or an amidation modification at the C-terminal amino acid residue at the first position.
  • the phosphorylation modification is a glycosylation modification and / or a phosphorylation modification at the N-terminal amino acid residues at position 3 and / or position 6.
  • the cyclization modification is a cyclization modification in which the C-terminal and N-terminal amino acid residues are connected, a cyclization modification in which the side chains of the 3rd and 5th amino acid residues at the N-terminus are connected, Cyclic modification linked to the side chain of the 6th amino acid residue at the N-terminus, and cyclic modification linked to the side chain of the 4th amino acid residue at the C-terminus and the 4th amino acid residue at the N-terminus NN-linked cyclization modification.
  • step (2) The polypeptide mixed stock solution obtained in step (1) was separated with dextran gel G25, and 0.02M HCl-water was used as an eluent. Samples were collected at a rate of 5mL / 20min, and one sample was collected every 20min. Combining the 37 to 39 parts of the eluate of the active section, and concentrating to obtain a crude extract of the active section of the polypeptide;
  • step (3) The crude extract of the active section of the polypeptide obtained in step (2) was dissolved in a 10 mM ammonium acetate buffer solution with a pH of 6.0, filtered through a 4.5 ⁇ m microporous membrane, and then separated by a Welch HILIC Amide column, and binary flow
  • the phases are ACN and ammonium acetate buffer solution with a concentration of 10 mM and pH 6.0.
  • the volume ratio of ACN to ammonium acetate buffer solution is 85:15 and the flow rate is 1 ml ⁇ min -1 .
  • the eluate with absorption peak at 210 nm is collected and screened.
  • the active bifunctional polypeptide is concentrated and dried to obtain a polypeptide with cardio-cerebral vascular protection function.
  • the acidic ethanol is an ethanol solution having a concentration of 45% to 55% by volume, and the pH is 4.8 to 5.2; more preferably, in the step (1), the pH of the acidic ethanol is adjusted.
  • the agent was acetic acid.
  • the extraction is extraction for 3 to 6 hours under stirring conditions of 28 to 32 ° C.
  • the ethanol is concentrated by rotary evaporation under conditions of 38 to 40 ° C.
  • decoloring is adding a diatomaceous earth-carboxymethyl starch sodium complex of 0.5 to 1% by mass to the solution, wherein the diatomaceous earth and the sodium carboxymethyl starch complex The mass ratio is 3: 2, and it is left at room temperature for 1.5 to 3 hours.
  • removing low-polar impurities is to extract 2 to 4 with hexane, and retain the water phase; more preferably, the added amount of hexane is 0.8 to 1.2 times the solution volume.
  • the conditions for the vacuum reduced pressure concentration are that the degree of vacuum is 0.08 to 0.1 MPa, and the temperature of the water bath is 40 to 45 ° C.
  • the specifications of the Welch HILIC and Amide column are 4.6 mm ⁇ 250 mm, 5 ⁇ m.
  • step (3) the screening of bifunctional polypeptides uses an activity-oriented technique, and the specific steps are as follows:
  • the ACE inhibitory activity evaluation model and the in vitro antioxidant activity evaluation model were used to determine the activity of each distillate segment, and the distillate segments with inhibition rates exceeding 80% in both evaluation models were screened.
  • the drying is freeze-dried at -20 ° C.
  • the present invention discloses for the first time a polypeptide compound containing 8 amino acid residues extracted from the snail, and it is found that the polypeptide compound can inhibit the production of angiotensin-converting enzymes and renin in blood vessels by removing ROS from the body.
  • Significant antihypertensive activity which can be used for the subsequent development of cardiovascular and cerebrovascular diseases and cardiovascular and cerebrovascular health products, has broad market prospects.
  • FIG. 1 photographs of raw snails used in the embodiment
  • A The overall appearance of B. snails; B. B. snails soft tissue; C. B. snails; D. S. snails;
  • Figure 2 is a molecular weight distribution test result of crude extract of the active section of the snail viscera
  • the upper figure is the HILIC chromatogram of the active extract; the lower figure is the histogram of the activity evaluation results of the chromatographic peaks of the crude extract;
  • FIG. 7 is a HILIC column detection result chart of each fractionated sample in Comparative Example 1;
  • HILIC chromatograms of samples 31 to 33 of A HILIC chromatograms of sample 34 to 36 of B;
  • FIG. 8 is a HILIC column detection result diagram of a middle-distillation section sample of Comparative Example 2;
  • a blank control B oxidative damage model group; C positive control group; D Example 1 group; E Example 2 group; F comparative example 1A group; G comparative example 1B group; H comparative example 1C group; I pair Ratio 1D group; J comparison 2 group;
  • Figure 10 is a graph of the effect of each sample on blood pressure in hypertensive rats.
  • the snails described in the examples were purchased from the Jinan Seafood Market in Shandong, and are generally commercially available products, as shown in FIG. 1.
  • the molecular weight (MW) distribution of the active segment obtained from the internal organs was measured by gel permeation chromatography (FIG. 2).
  • the mobile phase consisted of 0.1 mol ⁇ L -1 phosphate buffer (pH 6.7) and 0.1 mol ⁇ L -1 Na 2 SO 4 , and the flow rate was set to 0.2 mL ⁇ min -1 .
  • the lyophilized active peptide to be detected was dissolved in 6 mol ⁇ L -1 HCl (1 mg peptide / mL HCl), and hydrolyzed in a dry box at 110 ° C. for 24 hours.
  • the filtered hydrolyzed sample was evaporated on a rotary evaporator at 45 ° C.
  • the residue was dissolved in distilled water and lyophilized.
  • Samples and mixture amino acid standards were then derivatized with AQC and determined by RP-HPLC 18 .
  • the amino acid composition of the sample fraction was identified and quantified from a standard curve of mixed amino acids (Figure 3). All samples were determined in triplicate.
  • the EASY-Nlc1000 chromatography system (Thermo Finnigan, Bremen, Germany) and LTQ Orbitrap Velos Pro mass spectrometer (Thermo Finnigan, Bremen, Germany) were used to identify the amino acid sequence of the active peptide.
  • the purified peptide was dissolved in ultrapure water containing 0.1% trifluoroacetic acid at a concentration of 0.1 mg ⁇ mL -1 .
  • 2 ⁇ L of the sample was injected into a trapping column (100 ⁇ m ⁇ 20 mm, RP-C18, thermo Inc.) for pre-concentration.
  • the pre-concentrated sample was then automatically transferred to an analytical column (75 ⁇ m ⁇ 150 mm, RP-C18, thermo Inc.).
  • MS1 has a resolution of 60,000 at M / Z 400, and MS2 has unit mass resolution in the ion trap.
  • the first mass spectrum was collected in profile mode, and the second mass spectrum was collected in centroid mode to reduce the data file size.
  • Mascot 2.3 software (Matrix Science, USA) was used for data analysis.
  • the database is Mothidae, the enzyme is trypsin, and the maximum allowable missed site is 2.
  • Fixed modification Carbamidomethyl (C); Variable modification: Acetyl (Protein N-term), Deamidated (NQ), Dioxidation (W), Oxidation (M); MS tolerance is ⁇ 30ppm, MSMS tolerance is ⁇ 0.15 Da.
  • the NCBInr database is used for peptide identification. Only identified peptides with expected values below 0.05 are considered.
  • the BIOPEP database was used to find previously identified amino acid sequences with antioxidant and ACE inhibitory activity.
  • a method for extracting a polypeptide having cardio-cerebral vascular protection function the steps are as follows:
  • the acidic ethanol is a 55% by volume ethanol solution.
  • the acidic ethanol is adjusted to pH 4.8 with acetic acid and stirred at 32 ° C.
  • step (2) The polypeptide stock solution prepared in step (1) was separated with dextran gel G25, and 0.02M HCl-water was used as the eluent. Samples were collected at a rate of 5mL / 20min, and collected every 20min. In vitro antihypertensive and antioxidant dual-function activity tracking technology, the 37th to 39th fractions of the active section eluate were collected ( Figure 5), and concentrated under the conditions of a vacuum of 0.08MPa and a temperature of 45 ° C to obtain a peptide active section Crude extract
  • step (3) The crude extract of the peptide active section prepared in step (2) was dissolved in a 10 mM ammonium acetate buffer solution at pH 6.0, filtered through a 0.45 ⁇ m microporous membrane, and separated using a Welch HILIC Amide column.
  • the column size was 4.6. mm ⁇ 250mm, 5 ⁇ m
  • mobile phase is ACN and ammonium acetate buffer with a concentration of 10mM, pH 6.0
  • the volume ratio of ACN to ammonium acetate buffer is 85:15
  • the flow rate is 1ml ⁇ min -1
  • the detection wavelength is 210nm
  • the ACE inhibitory activity evaluation model and the in vitro antioxidant activity evaluation model were used to determine the activity of each chromatographic peak.
  • amino acid sequence of the polypeptide with cardio-cerebral vascular protection is shown in SEQ ID NO.1.
  • a method for extracting a polypeptide having cardio-cerebral vascular protection function the steps are as follows:
  • the acidic ethanol is a 45% by volume ethanol solution.
  • the acidic ethanol is adjusted to pH 5.2 with acetic acid and stirred at 28 ° C.
  • step (2) The polypeptide stock solution prepared in step (1) was separated with dextran gel G25, and 0.02M HCl-water was used as the eluent. Samples were collected at a rate of 5mL / 20min, and collected every 20min. In vitro antihypertensive and antioxidant dual-function activity tracking technology, the 37th to 39th fractions of the active section eluate were collected ( Figure 5), and concentrated under the conditions of a vacuum of 0.1 MPa and a temperature of 40 ° C to obtain a peptide active section Crude extract
  • step (3) The crude extract of the peptide active section prepared in step (2) was dissolved in a 10 mM ammonium acetate buffer solution at pH 6.0, filtered through a 0.45 ⁇ m microporous membrane, and separated using a Welch HILIC Amide column.
  • the column size was 4.6. mm ⁇ 250mm, 5 ⁇ m
  • mobile phase is ACN and ammonium acetate buffer with a concentration of 10mM, pH 6.0
  • the volume ratio of ACN to ammonium acetate buffer is 85:15
  • the flow rate is 1ml ⁇ min -1
  • the detection wavelength is 210nm
  • the ACE inhibitory activity evaluation model and the in vitro antioxidant activity evaluation model were used to determine the activity of each chromatographic peak.
  • amino acid sequence of the polypeptide with cardio-cerebral vascular protection is shown in SEQ ID NO.1.
  • the artificial amino acid sequence described in Example 2 is different in that the amino acid residue at the N-terminal first amino acid residue is acetylated.
  • the artificial amino acid sequence described in Example 2 is different in that the amino acid residue at the C-terminal first amino acid residue is amidated.
  • the artificial amino acid sequence as described in Example 2 is different in that the amino acid residue at the N-terminus at position 3 is glycosylated (A).
  • the artificial amino acid sequence as described in Example 2 is different in that the amino acid residue at position 3 at the N-terminus is phosphorylated.
  • the artificial amino acid sequence as described in Example 2 is different in that the amino acid residue at position 6 at the N-terminus is glycosylated.
  • the artificial amino acid sequence described in Example 2 is different in that the amino acid residue at the N-terminus amino acid residue at position 6 is phosphorylated.
  • A cyclization modification
  • B Cyclic modification
  • N N
  • C N-terminal Cyclic modification
  • D Residue side chain linked cyclization modification
  • E NN linked amino acid residues at the N-terminus at the N-terminus on the main chain at positions 2 and 7 (E).
  • the DPPH free radical scavenging activity of the sample polypeptide was measured according to the method described by Lee et al.
  • DPPH radical scavenging activity of the active peptide with a half inhibitory concentration represents, IC 50 is defined as the 50% inhibition of free radical formation of the desired peptide concentrations. See Table 1 for the DPPH radical scavenging IC 50 of Examples 1 and 2 and Comparative Examples 1 and 2.
  • the reducing ability of a polypeptide sample was determined using the method described by Moayedi et al.
  • a 100 ⁇ l polypeptide sample was mixed with 50 ⁇ l potassium phosphate buffer (0.2M, pH 6.6) and 150 ⁇ l potassium ferricyanide at a concentration of 1% (w / v) and incubated at 50 ° C. for 30 minutes. Then, 100 ⁇ l of 10% trichloroacetic acid (TCA) was added to the reaction mixture to stop the reaction. After centrifugation at 12,000 rpm for 10 minutes, 150 ⁇ l of the supernatant was removed. Then, 100 ⁇ l of ultrapure water and 50 ⁇ l of 0.1% (w / v) ferrous chloride were added to the supernatant.
  • TCA trichloroacetic acid
  • the control sample contained neither the peptide fraction nor ferric chloride.
  • the absorbance was measured at 700 nm and determined in triplicate. Although the peptide activity was determined by the reducing ability IC50, IC 50 is defined as an absorbance of the sample 0.5.
  • the reducing power IC 50 of Examples 1 and 2 and Comparative Examples 1 and 2 are shown in Table 1.
  • the hydroxyl radical scavenging activity of the polypeptide sample was detected according to the assay method described by Dong Z.Y.
  • polypeptide sample was mixed with 0.5 ml salicylic acid-ethanol (10 mM) and 0.5 ml FeSO 4 (10 mM). Then, after adding 0.5 ml of H 2 O 2 (8.8 mM), the mixture was incubated at 37 ° C. for 30 minutes. Ultrapure water was used instead of the fraction as a blank control, and a reaction mixture lacking H 2 O 2 was used as a control. The absorbance was measured at 510 nm and determined in triplicate. The hydroxyl radical scavenging activity of the peptide sample is calculated as follows:
  • Detection of in vivo antioxidant activity of a polypeptide sample was performed by using a transgenic zebrafish line Tg (krt4: NTR-hKikGR) cy17.
  • Transgenic zebrafish embryos developing 24hpf were distributed to 24-well cell culture plates (10 embryos / well) and incubated with 2 mL of 10 mM metronidazole (MTZ, dissolved in zebrafish culture water) and peptide samples at a dose of 100 ⁇ g ⁇ mL -1 at 28 ° C, after drug treatment for 24 hours.
  • Zebrafish treated with fish water without metronidazole and peptides were used as vehicle controls.
  • Zebrafish treated with peptide-free metronidazole were used as a negative control.
  • Vitmin C was used instead of the peptide as a positive control.
  • Each group was performed at least three times in parallel.
  • zebrafish embryos were anesthetized with tricaine (0.16%, w / v), then the fluorescence of the zebrafish embryos was observed and imaged using the FSX100 Bio Imaging Navigator instrument. The number of fluorescent spots was evaluated by using imagepro-plus software.
  • the in vivo antioxidant activity of a peptide sample is calculated as follows:
  • Antioxidant activity (FS s -FS nc ) / (FS vc -FS nc ) ⁇ 100
  • FS s is the fluorescent point of the sample (polypeptide sample)
  • FS nc is the fluorescent point of the negative control
  • FS vc is the fluorescent point (vitamin C).
  • ACE inhibitory activity of peptide samples was measured according to the method reported by Chen et al.
  • ACE inhibitory activity was determined by the following formula:
  • ACE inhibitory activity [(Ab-As) / (Ab-Ac)] ⁇ 100
  • the renin inhibitory activity of the polypeptide sample was determined according to the assay method described in the renin activity kit.
  • renin inhibitory activity was determined by the following formula:
  • Renin inhibitory activity [( ⁇ FI ⁇ min -1 b- ⁇ FI ⁇ min -1 s ) / ⁇ FI ⁇ min -1 b ] ⁇ 100
  • ⁇ FI ⁇ min -1 b and ⁇ FI ⁇ min -1 s are the renin activity change rates of the blank control and the sample, respectively.
  • Efficacy evaluation IC 50 activity by inhibiting peptide renin activity The IC 50 of the renin inhibition rate of Examples 1 and 2 and Comparative Examples 1 and 2 are shown in Table 1.
  • Spontaneously hypertensive rats were used to determine the in vivo hypotensive activity of peptide samples.
  • the results of evaluation of the antihypertensive and antioxidant activities of the polypeptides isolated from the snail viscera and the pulse red snails are shown in Table 1, and the results of the evaluation of the antihypertensive and antioxidant activities of the synthesized polypeptides are shown in Table 2.
  • the peptides having the characteristic peptide sequence prepared by the above method have significant in vivo and in vitro antihypertensive and antioxidant activities, and have potential cardio-cerebral vascular protection functions. They can be used as medicinal ingredients for the treatment of heart-brain Vascular disease drugs and health products. And by modifying the specific amino acid residues in the sequence, the biological activity of the polypeptide can be improved.
  • the polypeptide in which the Ala residue in the above amino acid sequence is replaced does not have antihypertensive and antioxidant activities, indicating that the above amino acid sequence has the specific properties of antihypertensive and antioxidant activity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明公开了一种具有心脑血管保护功能的多肽及其制备方法与应用。一种具有心脑血管保护功能的多肽，氨基酸序列如SEQ ID NO.1所示。本发明还公开了上述多肽作为药效成分在制备治疗心脑血管疾病药物或者作为保健成分在制备治疗心脑血管保健品中的应用。本发明首次公开了从香螺中提取的含有8个氨基酸残基的多肽化合物，通过检测发现，该多肽化合物可以通过清除体内ROS，抑制血管中血管紧张素转化酶、肾素的生成，具有非常显著的降压活性，可以进行后续治疗心脑血管疾病药物及心脑血管保健品的开发，具有广阔的市场前景。

Description

具有心脑血管保护功能的多肽及其制备方法与应用 技术领域
本发明涉及一种具有心脑血管保护功能的多肽及其制备方法与应用，属于功能多肽技术领域。
背景技术
目前发达国家和发展中国家死亡率和发病率排名前三位的慢性非传染性疾病(NCDs)是糖尿病、癌症、心血管和脑血管疾病。随着人口老龄化的发展以及社会经济和生活方式的不断变化，非传染性疾病的发病率将继续增加。预计到2030年，与非传染性疾病相关的死亡人数将增加到5200万。为了减轻非传染性疾病的负担，必须采取预防和治疗非传染性疾病有效措施。包括糖尿病、高血压、动脉粥样硬化等非传染性疾病的主要原因之一，是体内过量产生的活性氧(ROS)。因此，抑制ROS产生可用作NCDs的潜在预防和治疗措施。然而，许多合成抗氧化剂因其与健康有关的潜在风险而限制使用。因此，天然膳食抗氧化剂因其有益效果和更高的安全性而成为最佳选择。
海洋动植物品种繁多，富含的生物活性物质丰富。由于与陆地来源的动植物相比，生活环境显着不同，因此海洋动植物被认为是新型生物活性化合物来源的宝库。大量研究表明，具有抗氧化，抗高血压，抗糖尿病，抗菌和抗肿瘤生物活性的海洋生物活性肽具有很高的潜在价值，可用于预防和治疗非传染性疾病。此外，随着消费者对营养和健康的认识不断提高，对功能性食品和营养保健品的需求也在增长。最近研究越来越多地关注从饮食衍生的海洋生物中分离的生物活性肽。
软体动物是地球上第二大动物门。它不仅在维持生态平衡方面发挥着重要作用，而且作为一种可食性动物资源具有很大的商业价值。软体动物中有许多潜在的活性化合物，可用于膳食补充剂，功能性食品，营养品和药物。然而，目前公开的从具有应用价值的软体动物中分离潜在活性化合物的研究较少。
香螺(Neptunea arthritica cumingii)属软体动物门(Mollusca),腹足纲(Gastropoda),新腹足目(Neogastropoda),蛾螺科(Buccinida)，是一种大型捕食性腹足动物。它主要生活在中国，日本，朝鲜和韩国10至78米深的海域。在中国，香螺的主要分布于黄海和渤海区域，特别是辽宁大连和山东蓬莱。香螺的肉质肥厚紧致，味道鲜美，营养价值高，但孵化率低，因此具有较高的商业价值。到目前为止，大多数有关香螺的研究主要集中在其生物学上，如香螺的基因组，营养学，生殖特征等，或者是其营养成分，如粗蛋白，多糖，粗脂质，脂肪酸及氨基酸组成等。目前与香螺的活性成分相关的报道较少，只有早期研究发现香螺唾液中含有毒鼠强，组胺和胆碱衍生物具有神经活性。
发明内容
本发明针对现有技术的不足，提供一种具有心脑血管保护功能的多肽及其制备方法与应用。
本发明技术方案如下：
一种具有心脑血管保护功能的多肽，氨基酸序列如SEQ ID NO.1所示。SEQ ID NO.1：Tyr-Ile-Ala-Glu-Asp-Ala-Glu-Arg。
上述具有心脑血管保护功能的多肽的衍生物，对氨基酸序列如SEQ ID NO.1所示的多肽中的氨基酸残基进行修饰，修饰包括酰胺化修饰、羰基化修饰、磷酸化修饰和/环化修饰。
根据本发明优选的，所述酰胺化修饰为在N端第1位氨基酸残基进行乙酰化修饰或者在在C端第1位氨基酸残基进行酰胺化修饰。
根据本发明优选的，所述磷酸化修饰为在N端第3位和/或第6位氨基酸残基进行糖基化修饰和/或磷酸化修饰。
根据本发明优选的，所述环化修饰为在C端和N端氨基酸残基相连的环化修饰、N端第3位和第5位氨基酸残基的侧链间相连的环化修饰、N端和N端第6位氨基酸残基侧链相连的环化修饰、C端和N端第4位氨基酸残基侧链相连的环化修饰或者N端第2位和N端第7位氨基酸残基的N-N相连的环化修饰。
一种提取上述多肽的方法，步骤如下：
(1)将香螺去壳后，取内脏部分，磨碎，加入8～12倍重量的酸性乙醇，提取2.5～7h，过滤，取滤液，冰浴条件下静置10～60min，取上层清液，浓缩，脱色，离心，取上清液，去除低极性杂质，制得多肽混合原液；
(2)将步骤(1)制得的多肽混合原液用葡聚糖凝胶G25进行分离，以0.02M HCl-水为洗脱剂，按照5mL/20min的速度收集样品，每20min收集一份，将第37～39份的活性段洗脱液合并，经浓缩，制得多肽活性段粗提物；
(3)将步骤(2)制得的多肽活性段粗提物用浓度10mM、pH6.0的乙酸铵缓冲液溶解，经4.5μm微孔膜过滤，然后经Welch HILIC Amide柱分离，二元流动相为ACN和浓度10mM、pH6.0的乙酸铵缓冲液，ACN与乙酸铵缓冲液的体积比为85:15，流速为1ml·min -1，收集210nm处具有吸收峰的洗脱液，筛选活性双功能多肽，经浓缩、干燥，制得具有心脑血管保护功能的多肽。
根据本发明优选的，所述步骤(1)中，酸性乙醇为体积浓度45～55％的乙醇溶液，pH4.8～5.2；进一步优选的，所述步骤(1)中，酸性乙醇的pH调节剂为乙酸。
根据本发明优选的，所述步骤(1)中，所述提取为在28～32℃的搅拌条件下提取3～6h。
根据本发明优选的，所述步骤(1)中，浓缩为在38～40℃的条件下，旋转蒸发去除溶液中的乙醇。
根据本发明优选的，所述步骤(1)中，脱色为向溶液中加入质量百分比0.5～1％的硅藻土-羧甲基淀粉钠复合物，其中硅藻土与羧甲基淀粉钠的质量比为3:2，室温静置1.5～3h。
根据本发明优选的，所述步骤(1)中，去除低极性杂质为采用己烷萃取2～4，保留水相；进一步优选的，己烷的添加量为溶液体积的0.8～1.2倍。
根据本发明优选的，所述步骤(2)中，真空减压浓缩条件为真空度为0.08～0.1MPa，水浴温度为40～45℃。
根据本发明优选的，所述步骤(3)中，Welch HILIC Amide柱规格为4.6mm×250mm，5μm。
根据本发明优选的，所述步骤(3)中，筛选双功能多肽采用活性导向技术，具体步骤如下：
采用ACE抑制活性评价模型及体外抗氧化活性评价模型，测定各馏分段的活性，筛选出在2种评价模型中抑制率均超过80％的馏分段。
根据本发明优选的，所述步骤(3)中，干燥为在-20℃条件下冷冻干燥。
上述具有心脑血管保护功能的多肽及其衍生物作为药效成分在制备治疗心脑血管疾病药物中的应用。
上述具有心脑血管保护功能的多肽作为保健成分在制备心脑血管保健品中的应用。
有益效果
本发明首次公开了从香螺中提取的含有8个氨基酸残基的多肽化合物，通过检测发现，该多肽化合物可以通过清除体内ROS，抑制血管中血管紧张素转化酶、肾素的生成，具有非常显著的降压活性，可以进行后续治疗心脑血管疾病药物及心脑血管保健品的开发，具有广阔的市场前景。
附图说明
图1实施例中所用香螺原料照片；
图中：A、香螺整体外观；B香螺软组织；C香螺肉部；D香螺内脏；
图2香螺内脏活性段粗提物分子量分布检测结果图；
图3活性段提取物氨基酸组成结果图；
图4活性肽氨基酸序列MS/MS质谱结果图；
图5香螺内脏G25洗脱各馏分段抗氧化活性及体外降压检测结果图；
图中：A各馏分段280nm波长下吸光度值及DPPH自由基抑制率曲线图；
B各馏分段280nm波长下吸光度值及ACE抑制率曲线图；
图6香螺内脏活性段粗提物HILIC色谱柱检测结果及不同色谱峰活性评价结果图；
图中：上图为活性段提物HILIC色谱图；下图为粗提物各色谱峰活性评价结果柱状图；
图7对比例1中各馏分段样品的HILIC色谱柱检测结果图；
图中：A第31～33份样品的HILIC色谱图；B第34～36份样品的HILIC色谱图；
C第40～42份样品的HILIC色谱图；D第43～45份样品的HILIC色谱图；
图8对比例2中馏分段样品的HILIC色谱柱检测结果图；
图9各样品对斑马鱼体内氧化损伤修复效果图；
图中：A空白对照；B氧化损伤模型组；C阳性对照组；D实施例1组；E实施例2组；F对比例1A组；G对比例1B组；H对比例1C组；I对比例1D组；J对比例2组；
图10各样品对高血压大鼠血压的影响曲线图。
具体实施方式
下面结合实施例及说明书附图对本发明的技术方案做进一步阐述，但本发明呢所保护范围不限于此。
生物材料来源
实施例中所述香螺购自山东济南海鲜市场，普通市售产品，如图1所示。
检测方法
活性组分分子量分布检测方法
使用TSK-gel G2000 SW XL柱(7.8mm×250mm)(TOSOH，Yamaguchi，Japan)，采用凝胶渗透色谱法测定从内脏获得的活性段的分子量(MW)分布(图2)。流动相由0.1mol·L -1磷酸盐缓冲液(pH 6.7)和0.1mol·L -1Na 2SO 4组成，流速设定为0.2mL·min -1。
用核糖核酸酶(13700Da)，盐酸抑肽酶(6511Da)，血管紧张素II(1046Da)，HHL(430Da)和L-丝氨酸(105Da)为对照品，绘制洗脱体积-分子量曲线为In Mw＝17.50～0.089T(R 2＝0.9785,Mw为分子量，T为洗脱体积)。
活性组份氨基酸组成检测方法
将待检测的冻干活性肽溶解于6mol·L -1HCl中(1mg肽/mL HCl)，在110℃干燥箱中水解24小时。将过滤后的水解样品在45℃下通过旋转蒸发器蒸发。将残余物溶于蒸馏水中并冷冻干燥。然后，将样品和混合物氨基酸标准品用AQC衍生化并通过RP-HPLC 18测定。从混合氨基酸的标准曲线中鉴定和定量样品馏分的氨基酸组成(图3)。所有样品一式三份测定。
nano-LC-LTQ-Orbitrap-MS/MS鉴定活性肽的序列
采用EASY-Nlc1000色谱系统(Thermo Finnigan，Bremen，Germany)、LTQ Orbitrap Velos Pro质谱仪(Thermo Finnigan，Bremen，Germany)对活性肽的氨基酸序列鉴定。纯化的肽用含有0.1％三氟乙酸的浓度为0.1mg·mL -1的超纯水溶解。然后将2μL样品注入捕集柱(100μm×20mm，RP-C18，thermo Inc.)中进行预浓缩。随后预浓缩的样品自动进入分析柱(75μm×150mm，RP-C18，thermo Inc.)。以0.1％(v/v)甲酸在超纯水为洗脱剂，分析时长：60min，检测方式：正离子模式，喷雾电压：1.8kV，离子传输毛细管温度：250℃，使用前经标准校正液校正，母离子扫描范围：350-1800m/z，质谱扫描方式为信息依赖的采集工作模式下(IDA，Information Dependent Analysis)，每次全扫描(full scan)后采集最强的10个碎片图谱(MS2scan)，碎裂方式：碰撞诱导解离(CID，collision-induced dissociation)，正态化能量35％,q值0.25,活化时间：30ms，动态排除时间：30s。MS1在M/Z 400时分辨率为60,000，MS2在离子阱中为单位质量分辨。一级质谱采用profile模式采集，二级质谱采用centroid方式采集以降低数据文件大小。Mascot 2.3软件(Matrix Science，USA)用于数据分析。数据库为蛾螺科数据库，酶为胰蛋白酶，允许最大漏切位点为2。固定修饰为：Carbamidomethyl(C)；可变修饰为：Acetyl(Protein N-term)、Deamidated(NQ)、Dioxidation(W)、Oxidation(M)；MS容差为±30ppm，MSMS容差为±0.15Da。NCBInr数据库用于肽鉴定。仅考虑具有低于0.05的预期值的鉴定的肽。BIOPEP数据库用于寻找先前鉴定的具有抗氧化，ACE抑制活性的氨基酸序列。活性肽氨基酸序列MS/MS质谱结果见图4。
实施例1
一种提取具有心脑血管保护功能的多肽的方法，步骤如下：
(1)将香螺去壳后，取内脏部分，磨碎，加入8倍重量的酸性乙醇，酸性乙醇为体积浓度55％的乙醇溶液，酸性乙醇用乙酸调pH4.8，在32℃的搅拌条件下提取2.5h，过滤，取滤液， 冰浴条件下静置30min，取上层清液，在40℃的条件下，旋转蒸发去除溶液中的乙醇，然后按质量百分比0.5％的比例加入硅藻土-羧甲基淀粉钠复合物(质量比3:2)，室温静置3h，离心，取上清液，加入0.8倍体积的己烷萃取，保留水相，连续萃取4次，制得多肽混合原液；
(2)将步骤(1)制得的多肽混合原液用葡聚糖凝胶G25进行分离，以0.02M HCl-水为洗脱剂，按照5mL/20min的速度收集样品，每20min收集一次，采用体外降压及抗氧化双功能活性追踪技术，收集第37～39份的活性段洗脱液(图5)，在真空度为0.08MPa、温度为45℃的条件下浓缩，制得多肽活性段粗提液；
(3)将步骤(2)制得的多肽活性段粗提液用浓度10mM、pH6.0的乙酸铵缓冲液溶解，经0.45μm微孔膜过滤，采用Welch HILIC Amide柱分离，柱规格为4.6mm×250mm、5μm，流动相为ACN和浓度10mM、pH6.0的乙酸铵缓冲液，ACN与乙酸铵缓冲液的体积比为85:15，流速为1ml·min -1，检测波长为210nm，采用ACE抑制活性评价模型及体外抗氧化活性评价模型，测定各色谱峰的活性，筛选出在2种评价模型中抑制率均超过80％的色谱峰为保留时间17min处具有强吸收峰的色谱峰(图6)，收集相应的洗脱液，浓缩、-20℃条件下冷冻干燥，制得具有心脑血管保护功能的多肽。
经检测，具有心脑血管保护功能的多肽氨基酸序列如SEQ ID NO.1所示。
实施例2
采用刘振南等所述的Fmoc固相合成法(刘振南，黄强.Fmoc固相合成法.广西民族学院学报，1999，5(2)：110-112)，人工合成氨基酸序列如SEQ ID NO.1所示的多肽。
实施例3
一种提取具有心脑血管保护功能的多肽的方法，步骤如下：
(1)将香螺去壳后，取内脏部分，磨碎，加入12倍重量的酸性乙醇，酸性乙醇为体积浓度45％的乙醇溶液，酸性乙醇用乙酸调pH5.2，在28℃的搅拌条件下提取7h，过滤，取滤液，冰浴条件下静置30min，取上层清液，在38℃的条件下，旋转蒸发去除溶液中的乙醇，然后按质量百分比1％的比例加入活性炭，室温静置1.5h，离心，取上清液，加入1.2倍体积的己烷萃取，保留水相，连续萃取2次，制得多肽混合原液；
(2)将步骤(1)制得的多肽混合原液用葡聚糖凝胶G25进行分离，以0.02M HCl-水为洗脱剂，按照5mL/20min的速度收集样品，每20min收集一次，采用体外降压及抗氧化双功能活性追踪技术，收集第37～39份的活性段洗脱液(图5)，在真空度为0.1MPa、温度为40℃的条件下浓缩，制得多肽活性段粗提液；
(3)将步骤(2)制得的多肽活性段粗提液用浓度10mM、pH6.0的乙酸铵缓冲液溶解，经0.45μm微孔膜过滤，采用Welch HILIC Amide柱分离，柱规格为4.6mm×250mm、5μm，流动相为ACN和浓度10mM、pH6.0的乙酸铵缓冲液，ACN与乙酸铵缓冲液的体积比为85:15，流速为1ml·min -1，检测波长为210nm，采用ACE抑制活性评价模型及体外抗氧化活性评价模型，测定各色谱峰的活性，筛选出在2种评价模型中抑制率均超过80％的色谱峰为保留时间17min处具有强吸收峰的色谱峰(图6)，收集相应保留时间下的洗脱液，经浓缩、-20℃条件下冷冻干燥，制得具有心脑血管保护功能的多肽。
经检测，具有心脑血管保护功能的多肽氨基酸序列如SEQ ID NO.1所示。
实施例4
如实施例2所述的人工合成氨基酸序列，不同之处在于，在N端第1位氨基酸残基进行乙酰化修饰。
实施例5
如实施例2所述的人工合成氨基酸序列，不同之处在于，将C端第1位氨基酸残基进行酰胺化修饰。
实施例6
如实施例2所述的人工合成氨基酸序列，不同之处在于，将N端第3位氨基酸残基进行糖基化修饰(A)。
实施例7
如实施例2所述的人工合成氨基酸序列，不同之处在于，将N端第3位氨基酸残基进行磷酸化修饰。
实施例8
如实施例2所述的人工合成氨基酸序列，不同之处在于，将N端第6位氨基酸残基进行糖基化修饰。
实施例9
如实施例2所述的人工合成氨基酸序列，不同之处在于，将N端第6位氨基酸残基进行磷酸化修饰。
实施例10
如实施例2所述的人工合成氨基酸序列，不同之处在于，将直链氨基酸进行环化修饰，包括C端和N端氨基酸残基相连的环化修饰(A)、N端第3位和第5位氨基酸残基的侧链间相连的环化修饰(B)、N端和N端第6位氨基酸残基侧链相连的环化修饰(C)、C端和N端第4位氨基酸残基侧链相连的环化修饰(D)以及主链上的N端第2位和第7位氨基酸残基的N-N相连的环化修饰(E)。
对比例1
如实施例1所述的方法，不同之处在于，步骤(2)中所述的收集的洗脱液分别为第31～33份(A)，第34～36份(B)，第40～42份(C)以及第43～45份(D)，分别浓缩，制得相应的多肽混合物样品。按步骤(3)中所述纯化方法，在相同保留时间条件下，未见相应色谱峰(图7)。表明所述活性多肽仅存于720～780min馏分段中。故以步骤(2)所制得样品为供试品，用于下一步活性评价实验。
对比例2
如实施例1所述的方法，不同之处在于，步骤(1)中所述的实验原料为脉红螺内脏。按步骤(3)中所述纯化方法，在相同保留时间条件下，未见相应色谱峰(图8)。表明脉红螺内脏中不含有所述活性多肽。故以步骤(2)所制得样品为供试品，用于下一步活性评价实验。
对比例3
如实施例2所述的人工合成氨基酸序列，不同之处在于，将N端第3位和第6位氨基酸残基替换为Gly氨基酸残基。
实验例
DPPH自由基清除活性
根据Lee等人描述的方法检测样品多肽的DPPH自由基清除活性。
将200μl级分加入到含有200μl0.15mmol·L -1DPPH乙醇溶液的管中，并将混合物涡旋几秒钟。然后，将混合物在黑暗中于37℃温育12小时。超纯水用作对照。在517nm处测量吸光度，并一式三份进行测定。肽级分的DPPH自由基清除活性计算如下式：
DPPH自由基清除活性(％)＝(1-As/Ac)×100
其中As是样品的吸光度，Ac是对照的吸光度。虽然活性肽的DPPH自由基清除活性用半抑制浓度(IC50)表示，IC 50定义为抑制50％自由基形成所需的肽浓度。实施例1和2及对比例1和2的DPPH自由基清除率IC 50见表1。
还原能力检测
采用如Moayedi等人所述方法测定多肽样品的还原能力。
将100μl多肽样品与50μl磷酸钾缓冲液(0.2M，pH6.6)和150μl浓度1％(w/v)的铁氰化钾混合并在50℃温育30分钟。然后，向反应混合物中加入100μl10％三氯乙酸(TCA)以终止该反应。在12,000rpm离心10分钟后，取出150μl上清液。然后，将100μl超纯水和50μl浓度0.1％(w/v)氯化亚铁加入上清液中。
对照样品既不包含肽级分也不包含氯化铁。在700nm下测量吸光度，一式三份进行测定。虽然通过IC50测定活性肽的还原能力，IC 50定义为0.5所需样品的吸光度。实施例1和2及对比例1和2的还原力IC 50见表1。
羟基自由基清除活性
根据Dong Z.Y.所述测定方法检测多肽样品羟自由基清除活性。
将1mL多肽样品与0.5ml水杨酸-乙醇(10mM)和0.5ml FeSO 4(10mM)混合。然后，在加入0.5ml H 2O 2(8.8mM)中后，将混合物在37℃温育30分钟。使用超纯水代替馏分作为空白对照，并且将缺乏H 2O 2的反应混合物用作对照。在510nm处测量吸光度，并一式三份进行测定。多肽样品的羟基自由基清除活性计算如下式：
羟基自由基清除活性(％)＝[1-(A s-A c)/A bc]×100
其中As是样品的吸光度，Ac是对照的吸光度，Abc是空白对照的吸光度。通过IC 50评估活性肽的羟基自由基活性。实施例1和2及对比例1和2的羟基自由基清除率IC 50见表1。
体内抗氧化活性的测定
通过使用转基因斑马鱼系Tg(krt4：NTR-hKikGR)cy17，进行多肽样品的体内抗氧化的检测。
将发育24hpf的转基因斑马鱼胚胎分配到24孔细胞培养板(10个胚胎/孔)中，并与2mL10mM甲硝唑(MTZ，溶于斑马鱼培养水)和多肽样品一起孵育，剂量为100μg·mL -1，28℃条件下，药物处理24小时后。用没有甲硝唑和肽的鱼水处理的斑马鱼用作媒介物对照。用不 含肽的甲硝唑处理的斑马鱼用作阴性对照。用Vitmin C代替肽作为阳性对照。每组至少进行三次平行重复。孵育后，用三卡因(0.16％，w/v)麻醉斑马鱼胚胎，然后观察斑马鱼胚胎的荧光并使用FSX100 Bio Imaging Navigator仪器成像。通过使用imagepro-plus软件评估荧光斑点的数量。多肽样品的体内抗氧化活性计算如下式：
抗氧化活性(％)＝(FS s-FS nc)/(FS vc-FS nc)×100
其中FS s是样品的荧光点(多肽样品)，FS nc是阴性对照的荧光点，FS vc是荧光点(维生素C)。实施例1和2及对比例1和2的体内抗氧化评价结果见图9。
ACE抑制活性的测定
根据Chen等报道的方法测量多肽样品ACE抑制活性。
将50μL肽和50μLACE溶液(25mU·mL -1)混合并在37℃下孵育5分钟。然后，将含有0.5M NaCl(pH8.3)的50mM硼酸钠缓冲液中的125μL8.3mMHHL加入混合物中以开始反应并在37℃下孵育60分钟。然后，通过添加125μL的1M HCl终止反应。通过使用750μL乙酸乙酯提取Hippuric acid(HA)。离心后，转移500μL上层，在室温下真空蒸发乙酸乙酯。将残余物溶于1.5mL超纯水中，在228nm处测量吸光度。通过下式测定ACE抑制活性：
ACE抑制活性(％)＝[(Ab-As)/(Ab-Ac)]×100
其中Ab和As是没有和具有HHL和Ac的混合物的吸光度是没有ACE的混合物的吸光度。通过IC 50评估活性肽的ACE抑制活性的效力。实施例1和2及对比例1和2的ACE抑制率IC 50见表1。
肾素活性的测定
根据肾素活性试剂盒所述的测定方法测定多肽样品的肾素抑制活性。
将10μL肽、20μL底物溶液和150μL缓冲液充分混合，随后加入10μL肾素启动反应，于37℃下孵育15min，在10min中内，采用荧光酶标仪测定反应体系的荧光强度，激发波长为340nm，发射波长为490nm。以纯水替代样品作为空白对照。通过下式测定肾素抑制活性：
肾素抑制活性(％)＝[(△FI·min -1 b-△FI·min -1 s)/△FI·min -1 b]×100
其中△FI·min -1 b和△FI·min -1 s分别为空白对照和样品的肾素活性变化速率。通过IC 50评估活性肽的肾素抑制活性的效力。实施例1和2及对比例1和2的肾素抑制率IC 50见表1。
体内降压活性的测定
采用自发性高血压大鼠(SHR)测定多肽样品的体内降压活性。
于实验前一周，每两天测定大鼠的血压，待血压稳定后，将体重为270-320g的SHR随机分为样品组，阳性对照组和空白组(n＝5)。灌胃前，先测定大鼠血压，随后样品组按照10mg·kg -1的剂量，连续灌胃5d。阳性对照组大鼠灌胃剂量为3mg·kg -1卡托普利，空白组大鼠灌胃纯净水。每天测定各实验组的大鼠的血压。给药期间，实施例1和2及对比例1和2对高血压大鼠血压的影响见图10。
统计分析
所有测试重复三次，结果表示为平均值±标准偏差。SPSS 16.0(SPSS Inc.，Chicago，IL，USA)用于统计分析。所有数据均由Origin 9.0(Origin Lab，Northampton，MA，USA)制 作。单因素方差分析(ANOVA)用于分析差异。P值小于0.05被认为是统计学上显着的。Pearson相关系数用于评估内容和活动之间的相关性。线性回归方程通过线性回归分析计算。
实验结果
从香螺内脏及脉红螺内脏中分离纯化的多肽的降压及抗氧化活性评价结果见表1，合成的多肽的降压及抗氧化活性评价结果见表2。根据实验结果可知，由上述方法所制备的特征肽段序列的多肽具有显著的体内、体外降压及抗氧化活性，具有潜在的心脑血管保护功能，可作为药效成分用于制备治疗心脑血管疾病药物及保健品。并且通过对上述序列中的特定氨基酸残基进行结构修饰，可以提高多肽的生物活性。将上述氨基酸序列中的Ala残基进行替换后的多肽不具备降压及抗氧化活性，表明上述氨基酸序列降压及抗氧化活性的专属性。
表1 天然来源样品体外降压及抗氧化活性评价结果(IC 50值，n＝3，
Figure PCTCN2019106234-appb-000001
)
Figure PCTCN2019106234-appb-000002
Figure PCTCN2019106234-appb-000003
代表与实施例1相比有显著性差异P<0.01，
Figure PCTCN2019106234-appb-000004
代表与实施例2相比有显著性差异P<0.01。
表2 合成多肽的体外降压及抗氧化活性评价结果(IC 50值，n＝3，
Figure PCTCN2019106234-appb-000005
)
Figure PCTCN2019106234-appb-000006
Figure PCTCN2019106234-appb-000007

Claims (10)

  1. 一种具有心脑血管保护功能的多肽，氨基酸序列如SEQ ID NO.1所示。
  2. 权利要求1所述具有心脑血管保护功能的多肽的衍生物，对氨基酸序列如SEQ ID NO.1所示的多肽中的氨基酸残基进行修饰，修饰包括酰胺化修饰、羰基化修饰、磷酸化修饰和/环化修饰。
  3. 如权利要求2所述的衍生物，其特征在于，所述酰胺化修饰为在N端第1位氨基酸残基进行乙酰化修饰或者在在C端第1位氨基酸残基进行酰胺化修饰。
  4. 如权利要求2所述的衍生物，其特征在于，所述磷酸化修饰为在N端第3位和/或第6位氨基酸残基进行糖基化修饰和/或磷酸化修饰。
  5. 如权利要求2所述的衍生物，其特征在于，所述环化修饰为在C端和N端氨基酸残基相连的环化修饰、N端第3位和第5位氨基酸残基的侧链间相连的环化修饰、N端和N端第6位氨基酸残基侧链相连的环化修饰、C端和N端第4位氨基酸残基侧链相连的环化修饰或者N端第2位和N端第7位氨基酸残基的N-N相连的环化修饰。
  6. 一种提取上述多肽的方法，其特征在于，步骤如下：
    (1)将香螺去壳后，取内脏部分，磨碎，加入8～12倍重量的酸性乙醇，提取2.5～7h，过滤，取滤液，冰浴条件下静置10～60min，取上层清液，浓缩，脱色，离心，取上清液，去除低极性杂质，制得多肽混合原液；
    (2)将步骤(1)制得的多肽混合原液用葡聚糖凝胶G25进行分离，以0.018～0.022M HCl-水为洗脱剂，按照5mL/20min的速度收集样品，每20min收集一份，将第37～39份的活性段洗脱液合并，经浓缩，制得多肽活性段粗提物；
    (3)将步骤(2)制得的多肽活性段粗提物用浓度10mM、pH5.8～6.2的乙酸铵缓冲液溶解，经4.5μm微孔膜过滤，然后经Welch HILIC Amide柱分离，二元流动相为ACN和浓度10mM、pH5.8～6.2的乙酸铵缓冲液，ACN与乙酸铵缓冲液的体积比为85:15，流速为1ml·min -1，收集210nm处具有吸收峰的洗脱液，筛选活性双功能多肽，经浓缩、干燥，制得具有心脑血管保护功能的多肽。
  7. 如权利要求6所述的方法，其特征在于，所述步骤(1)中，酸性乙醇为体积浓度45～55％的乙醇溶液，pH4.8～5.2；进一步优选的，所述步骤(1)中，酸性乙醇的pH调节剂为乙酸；
    优选的，所述步骤(1)中，所述提取为在28～32℃的搅拌条件下提取3～6h；
    优选的，所述步骤(1)中，浓缩为在38～40℃的条件下，旋转蒸发去除溶液中的乙醇；
    优选的，所述步骤(1)中，脱色为向溶液中加入质量百分比0.5～1％的硅藻土-羧甲基淀粉钠复合物，其中硅藻土与羧甲基淀粉钠的质量比为3:2，室温静置1.5～3h；
    优选的，所述步骤(1)中，去除低极性杂质为采用己烷萃取2～4，保留水相；进一步优选的，己烷的添加量为溶液体积的0.8～1.2倍；
  8. 如权利要求6所述的方法，其特征在于，所述步骤(2)中，真空减压浓缩条件为真空度为0.08～0.1MPa，水浴温度为40～45℃；
    优选的，所述步骤(3)中，Welch HILIC Amide柱规格为4.6mm×250mm，5μm。
    优选的，所述步骤(3)中，筛选双功能多肽采用活性导向技术，具体步骤如下：
    采用ACE抑制活性评价模型及体外抗氧化活性评价模型，测定各馏分段的活性，筛选出在2种评价模型中抑制率均超过80％的馏分段；
    优选的，所述步骤(3)中，干燥为在-20℃条件下冷冻干燥。
  9. 权利要求1所述具有心脑血管保护功能的多肽、权利要求2～5任意之一所述多肽衍生物作为药效成分在制备治疗心脑血管疾病药物中的应用。
  10. 权利要求1所述具有心脑血管保护功能的多肽、权利要求2～5任意之一所述多肽衍生物作为保健成分在制备心脑血管保健品中的应用。
PCT/CN2019/106234 2018-08-13 2019-09-17 具有心脑血管保护功能的多肽及其制备方法与应用 WO2020035079A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810916171.7A CN109021070B (zh) 2018-08-13 2018-08-13 具有心脑血管保护功能的多肽及其制备方法与应用
CN201810916171.7 2018-08-13

Publications (1)

Publication Number Publication Date
WO2020035079A1 true WO2020035079A1 (zh) 2020-02-20

Family

ID=64632983

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/106234 WO2020035079A1 (zh) 2018-08-13 2019-09-17 具有心脑血管保护功能的多肽及其制备方法与应用

Country Status (2)

Country Link
CN (1) CN109021070B (zh)
WO (1) WO2020035079A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109021070B (zh) * 2018-08-13 2019-05-14 山东省科学院生物研究所 具有心脑血管保护功能的多肽及其制备方法与应用
CN111423495B (zh) * 2020-04-20 2022-06-28 山东省科学院生物研究所 具有抗氧化应激损伤的脉红螺多肽及其制备方法与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104961802A (zh) * 2015-07-05 2015-10-07 查文娟 一种治疗癌症的活性肽及其用途
CN105311617A (zh) * 2014-06-20 2016-02-10 浙江海洋学院 一种泥螺寡肽在抗肺癌中的应用
CN108853473A (zh) * 2018-08-13 2018-11-23 山东省科学院生物研究所 一种活性八肽在保护感觉毛细胞方面的应用
CN109021070A (zh) * 2018-08-13 2018-12-18 山东省科学院生物研究所 具有心脑血管保护功能的多肽及其制备方法与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106084013B (zh) * 2016-08-26 2019-03-29 南京中医药大学 血管紧张素转化酶抑制肽及其制备方法和应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105311617A (zh) * 2014-06-20 2016-02-10 浙江海洋学院 一种泥螺寡肽在抗肺癌中的应用
CN104961802A (zh) * 2015-07-05 2015-10-07 查文娟 一种治疗癌症的活性肽及其用途
CN108853473A (zh) * 2018-08-13 2018-11-23 山东省科学院生物研究所 一种活性八肽在保护感觉毛细胞方面的应用
CN109021070A (zh) * 2018-08-13 2018-12-18 山东省科学院生物研究所 具有心脑血管保护功能的多肽及其制备方法与应用

Also Published As

Publication number Publication date
CN109021070A (zh) 2018-12-18
CN109021070B (zh) 2019-05-14

Similar Documents

Publication Publication Date Title
Abuine et al. Biological activity of peptides purified from fish skin hydrolysates
Alemán et al. Contribution of Leu and Hyp residues to antioxidant and ACE-inhibitory activities of peptide sequences isolated from squid gelatin hydrolysate
Zhang et al. Gelatins and antioxidant peptides from Skipjack tuna (Katsuwonus pelamis) skins: Purification, characterization, and cytoprotection on ultraviolet-A injured human skin fibroblasts
Freitas et al. Antioxidative peptides: Trends and perspectives for future research
Hao et al. A comprehensive review of oyster peptides: Preparation, characterisation and bioactivities
Trinidad-Calderon et al. Maize bioactive peptides: From structure to human health
Zheng et al. ACE-inhibitory and antioxidant peptides from coconut cake albumin hydrolysates: purification, identification and synthesis
Zhang et al. Purification and identification of dipeptidyl peptidase IV and angiotensin-converting enzyme inhibitory peptides from silver carp (Hypophthalmichthys molitrix) muscle hydrolysate
Wu et al. Purification and characterization of two novel angiotensin I-converting enzyme inhibitory peptides derived from R-phycoerythrin of red algae (Bangia fusco-purpurea)
CN111647043B (zh) 含有Hyp-Gly序列的一类抗血小板和抗血栓功能的寡肽
Shi et al. Purification and the secondary structure of a novel angiotensin I-converting enzyme (ACE) inhibitory peptide from the alcalase hydrolysate of seahorse protein
JP2002519438A (ja) 人ラクトフェリンの配列に基づくペプチドおよびその使用
CN111423495B (zh) 具有抗氧化应激损伤的脉红螺多肽及其制备方法与应用
WO2020035079A1 (zh) 具有心脑血管保护功能的多肽及其制备方法与应用
WO2007037297A1 (ja) 成人病の予防及び治療に有効な組成物
Kim et al. Identification of four new angiotensin I-converting enzyme inhibitory peptides from fermented anchovy sauce
CN111518164A (zh) Ace抑制肽p2、其应用及其制备方法
AU2019243671A1 (en) Bioactive green-lipped mussel extracts and uses thereof
Xu et al. Isolation, identification and molecular docking of anti-inflammatory peptides from walnut (Juglans regia L.) meal hydrolysates
KR101795655B1 (ko) 어류부산물을 이용한 의료용 마린콜라겐과 이의 제조방법
CN109180781B (zh) 具有修复氧化损伤功能的多肽及其制备方法与应用
Chen et al. Characterization of ACE inhibitory peptide from Cassia tora L. globulin fraction and its antihypertensive activity in SHR
Mustafa et al. Bioactive peptides and their natural sources
CN111499691B (zh) Ace抑制肽p1、其应用及其制备方法
CN110655553B (zh) 一种芝麻来源的ace抑制肽、制备方法及其在制备降血压药物方面的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19849730

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19849730

Country of ref document: EP

Kind code of ref document: A1